Some of the Novavax data shows that it generates a stronger antibody signature with broader coverage because it contains the full length spike. Even though it does not contain the nuclucaspid or other proteins it appears supperior against Omicron and potentially future varriants.

I've been in a Novavax facebook group for a while.

They had 30K people in Phase III trials.
Many of the people in UK trial participants went on to take the mRNA after waiting months for approval because they wanted to travel, etc.

Almost all said the 'expected' side effects were much less with Novavax; More typical vs the extreme side effects. They reported how much more the mRNA knocked them on their a$$.

So far no incidence of myocarditis reported; but with a sample size of 30K (not sure how many were 16-26) it's probably underpowered to be sure.

Personally although I've been following Novavax, I'm more interested in Israel's Migvax or Oravax; Oravax is an *ORAL* Virus-like-particle (VLP) that has 3 proteins (spike, nuclocaspid).

Israel should have fast tracked their own products instead of jumping in with Pfizer.